Imaging Histone Deacetylase in the Heart
Recruiting · NCT03549559 · Interventional (participants receive a specific treatment) · Lead sponsor: Massachusetts General Hospital
View the official record on ClinicalTrials.gov →Interventions studied
11C-MartinostatPET-MRI
What this trial is about
The overall goal of this PET-MR imaging trial is to evaluate 11C-Martinostat, a histone deacetylase targeted radioligand, in patients with aortic stenosis, individuals with diabetes, and healthy volunteers.
Who can take part
Age range
18 Years to 85 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Group 1: Healthy Volunteers (n = 30)
- Healthy adults with no known history of medical disease
- Age 18-85 years
- No history cardiovascular disease
- Ability to provide informed consent
- Group 2: Patients with Diabetes (n = 16)
- Age 18-85 years
- Diagnosis of diabetes
- Echocardiogram within last 12 months showing no evidence of left ventricular hypertrophy or hemodynamic findings consistent with heart failure with preserved ejection fraction
- Ability to provide informed consent
- Group 3: Patients with Aortic Stenosis (n = 50)
- Age 18-85 years
- Echocardiogram or cardiac MRI scan within last 12 months documenting left ventricular hypertrophy and degenerative calcific aortic stenosis
- Ability to provide informed consent
Exclusion criteria
- Known contraindication to MRI
Where it is running
1 location listed across 1 US state.
- Massachusetts General Hospital - Boston, Massachusetts, United States